Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
MMochida Pharmaceutical Co.,Ltd. logo
4534TSE Prime

Mochida Pharmaceutical Co.,Ltd.

持田製薬 Yahoo Finance

Recent & upcoming events

Aug 3
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 24
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
May 15
Earnings 2:00
FY earnings announcement (scheduled)
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Oct 19
Est.
Earnings 2:00 approx.
Q2 earnings
Add to Google Calendar
2027
Jan 11
Est.
Earnings 1:00 approx.
Q3 earnings
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Earnings 2:00 approx.
Q3 earnings
Add to Google Calendar
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
Jun 21
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar

KPI highlights

FY26
Revenue ¥116.95B YoY +11.2%
Operating income ¥10.15B margin 8.7%
Net income ¥7.90B YoY +39.0%
EPS ¥223 YoY +39.0%
P/E —
ROE 5.8% Equity ratio 77% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥126.00B +7.7%
Operating income ¥10.50B +3.5%
Net income ¥10.00B +26.5%
EPS ¥283 +26.9%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q2
Revenue ¥24.75B¥24.73B¥28.74B¥24.67B——
Operating income ¥2.52B¥1.44B¥1.84B¥11M——
Net income ¥1.69B¥1.15B¥1.61B¥103M——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2021–2026）

事業法人 5.6%国内機関 16.9%個人 7.8%その他 20.8%未開示 48.9%202120222023202420252026
事業法人国内機関個人その他未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

公益財団法人持田記念医学薬学振興財団 16.1%公益財団法人持田記念医学薬学振興財団日本マスタートラスト信託銀行株式会社 8.4%日本マスタートラスト信託銀行株式会社(信託口)公益財団法人高松宮妃癌研究基金 4.8%公益財団法人高松宮妃癌研究基金株式会社三菱UFJ銀行 4.5%株式会社三菱UFJ銀行みずほ信託銀行株式会社　退職給付信託 4.1%みずほ信託銀行株式会社　退職給付信託みずほ銀行口　再信託受託者株式会社日本カストディ銀行株式会社ニッスイ 3.4%株式会社ニッスイ持田　直幸 2.9%持田　直幸持田　健志 2.7%持田　健志持田　和枝 2.2%持田　和枝大正製薬ホールディングス株式会社 2.2%大正製薬ホールディングス株式会社202120222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
公益財団法人持田記念医学薬学振興財団 5,688,000 16.1% Yuho (EDINET)
日本マスタートラスト信託銀行株式会社(信託口) 2,981,000 8.4% Yuho (EDINET)
公益財団法人高松宮妃癌研究基金 1,683,000 4.8% Yuho (EDINET)
株式会社三菱UFJ銀行 1,586,000 4.5% Yuho (EDINET)
みずほ信託銀行株式会社 退職給付信託みずほ銀行口 再信託受託者株式会社日本カストディ銀行 1,434,000 4.1% Yuho (EDINET)
株式会社ニッスイ 1,200,000 3.4% Yuho (EDINET)
持田 直幸 1,023,000 2.9% Yuho (EDINET)
持田 健志 949,000 2.7% Yuho (EDINET)
持田 和枝 787,000 2.2% Yuho (EDINET)
大正製薬ホールディングス株式会社 785,000 2.2% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

3/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 4.3%
✗ Positive operating cash flow ¥-7.35B
✓ ROA improved YoY 3.6% → 4.3%
✗ Operating CF exceeds net income (accrual quality) OCF ¥-7.35B / net income ¥7.90B
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 81.6% → 76.8%
✗ Current ratio improved 4.81× → 4.29×
✓ No dilution (shares outstanding did not increase) 36,390,000 → 36,390,000
✗ Gross margin improved 51.1% → 48.1%
✗ Asset turnover improved 0.66× → 0.64×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio 76.8%
Current ratio 4.3×
Years of positive operating CF 8 of last 10 yrs
Payout ratio 43%
Latest fiscal year result Profit (net income ¥7.90B)

Performance history

Last 10 years
0億円292億円585億円877億円1,170億円 FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Revenue 9731,0681,0961,0181,0301,1021,0331,0291,0521,170
Operating income 11411710688.112014485.158.081.3101
Ordinary income 11612010991.512314890.960.480.7112
Net income 85.390.284.446.085.910666.545.556.979.0
Total assets 1,4841,5511,5901,5751,6181,6311,5881,5881,6011,827
Equity 1,1191,1971,2511,2071,2701,2861,2681,2801,3071,403

Indicators & cash flow

*Split-adjustedUnit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
EPS ¥215¥227¥213¥118¥222¥277¥179¥127¥160¥223
ROE 7.9%7.8%6.9%3.7%6.9%8.3%5.2%3.6%4.4%5.8%
Operating CF 55.832.812693.592.074.673.0-74.893.5-73.5
Investing CF -18.4-4.26-11.2-17.6-8.80-20.1-29.50.74174-168
Financing CF -32.9-34.8-60.9-53.3-51.1-59.6-68.8-63.9-28.770.3
FCF 37.528.611475.983.254.543.5-74.1267-242

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data